---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-035530"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T16:19:26.617922+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Acura Pharmaceuticals receives $250k loan from major shareholder; warns of possible bankruptcy if no further funding

## Summary
- Total note principal now $5,419,279 after 13th loan from AD Pharma (65% owner).
- Loan matures March 31, 2024; funds used for operations only through mid-April.
- Without additional funding by end of April, operations may cease or bankruptcy filed.
- Default interest rate 7.5%; events include failure to pay, bankruptcy, inability to pay debts.
- AD Pharma, controlled by Mr. Schutte, holds ~65% equity; Schutte personally owns ~13%.

## SEC filing metadata
- accession: 0001104659-24-035530
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465924035530/0001104659-24-035530-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465924035530/tm249122d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-035530
- JSON: https://secwatch.observer/filing/0001104659-24-035530.json
- Plain text: https://secwatch.observer/filing/0001104659-24-035530.txt

## Key facts
- Debt Financings
  ACURA PHARMACEUTICALS, INC incurred loan of $250,000 with Abuse Deterrent Pharma, LLC at 5.25% maturing March 31, 2024.
  - Instrument: loan
  - Principal: $250,000
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Rate: 5.25%
  - Maturity: March 31, 2024
  - Event: incurrence
  source text: On March 14, 2024 we received a $250,000 loan from Abuse Deterrent Pharma, LLC (“AD Pharma”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465924035530/0001104659-24-035530-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.